High Dephosphorylated-Uncarboxylated MGP in Hemodialysis patients: risk factors and response to vitamin K2, A pre-post intervention clinical trial

Mabel Aoun, Maha Makki, Hiba Azar, Hiam Matta, Dania Nehme Chelala, Mabel Aoun, Maha Makki, Hiba Azar, Hiam Matta, Dania Nehme Chelala

Abstract

Background: Vascular calcifications are highly prevalent in hemodialysis patients. Dephosphorylated-uncarboxylated MGP (dp-ucMGP) was found to increase in vitamin K-deficient patients and may be associated with vascular calcifications. Supplementation of hemodialysis patients with vitamin K2 (menaquinone-7) has been studied in Europe with a maximum 61% drop of dp-ucMGP levels. The aim of this study is to assess first the drop of dp-ucMGP in an Eastern Mediterranean cohort after vitamin K2 treatment and second the correlation between baseline dp-ucMGP and vascular calcification score.

Methods: This is a prospective, pre-post intervention clinical trial involving 50 hemodialysis patients who received daily 360 μg of menaquinone-7 for 4 weeks. At baseline they were assessed for plasma dp-ucMGP levels and vascular calcification scores (AC-24) as well as for other demographic, clinical and biological variables. Dp-ucMGP levels were measured a second time at 4 weeks.

Results: At baseline, dp-ucMGP levels were extremely elevated with a median of 3179.15 (1825.25; 4339.50) pM and correlated significantly with AC-24 (Spearman's rho = 0.43, P = 0.002). Using a bivariate regression analysis, the association between dp-ucMGP levels and AC-24 was most significant when comparing dp-ucMGP levels less than 1000 to those more than 1000 pM (P = 0.02). Dp-ucMGP levels higher than 5000 pM were significantly associated with females, patients with recent fracture and patients with lower serum albumin (respectively P = 0.02, 0.004 and 0.046). The average drop of dp-ucMGP at 4 weeks of treatment was found to be 86% with diabetics having the lowest drop rate (P = 0.01).

Conclusion: Vitamin K deficiency, as assessed by high dp-ucMGP levels, is profound in hemodialysis patients from the Eastern Mediterranean region and it is significantly correlated with vascular calcifications. Daily 360 μg of menaquinone-7, given for 4 weeks, effectively reduces dp-ucMGP in this population. Future studies are needed to assess the changes in vascular calcifications in hemodialysis patients treated with vitamin K2 over a longer follow-up period.

Trial registration: The clinical trial was registered on clinicaltrials.gov (Identification number NCT02876354 , on August 11, 2016).

Keywords: Dephosphorylated Uncarboxylated matrix Gla protein; Hemodialysis; Menaquinone-7; Pre-post intervention clinical trial; Vascular calcifications; Vitamin K2.

Figures

Fig. 1
Fig. 1
Scatter plot for the association between calcification score (AC-24) and dp-ucMGP level (pM) at baseline (Spearman correlation coefficient = 0.43, p = 0.002)
Fig. 2
Fig. 2
Scatter plot for the association between aortic calcification score (AC-24) and dp-ucMGP drop (Spearman correlation coefficient = 0.19, p = 0.18)

References

    1. Jean G, Bresson E, Terrat JC, et al. Peripheral vascular calcification in long-hemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant. 2009;24:948–955. doi: 10.1093/ndt/gfn571.
    1. Noordzij M, Cranenburg EM, Engelsman LF, et al. Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients. Nephrol Dial Transplant. 2011;26(5):1662–1669. doi: 10.1093/ndt/gfq582.
    1. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38(4):938–942. doi: 10.1161/hy1001.096358.
    1. Nasir K, Rubin J, Blaha MJ, Shaw LJ, et al. Interplay of coronary artery calcification and traditional risk factors for the prediction of all-cause mortality in asymptomatic individuals. Circ Cardiovasc Imaging. 2012;5:467–473. doi: 10.1161/CIRCIMAGING.111.964528.
    1. KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney Int. 2009;76(Suppl 113):S1–S130.
    1. Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382:1268–1277. doi: 10.1016/S0140-6736(13)60897-1.
    1. Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011;26:1327–1339. doi: 10.1093/ndt/gfq725.
    1. Nigwekar SU, Bhan I, Turchin A, et al. Statin use and calcific uremic arteriolopathy: a matched case-control study. Am J Nephrol. 2013;37:325–332. doi: 10.1159/000348806.
    1. Palit S, Kendrick J. Vascular calcification in chronic kidney disease: role of disordered mineral metabolism. Curr Pharm Des. 2014;20(37):5829–5833. doi: 10.2174/1381612820666140212194926.
    1. Krueger T, Westenfeld R, Ketteler M, et al. Vitamin K deficiency in CKD patients: a modifiable risk factor for vascular calcification? Kidney Int. 2009;76:18–22. doi: 10.1038/ki.2009.126.
    1. Schurgers LJ, Barreto DV, Barreto FC, et al. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol. 2010;5:568–575. doi: 10.2215/CJN.07081009.
    1. Rennenberg RJ, de Leeuw PW, Kessels AG, et al. Calcium scores and matrix Gla protein levels: association with vitamin K status. Eur J Clin Investig. 2010;40:344–349. doi: 10.1111/j.1365-2362.2010.02275.x.
    1. Delanaye P, Krzesinski JM, Warling X, et al. Dephosphorylated-uncarboxylated matrix Gla protein concentration is predicitive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients. BMC Nephrol. 2014;15:145. doi: 10.1186/1471-2369-15-145.
    1. Theuwissen E, Smit E, Vermeer C. The role of vitamin K in soft-tissue calcification. Adv Nutr. 2012;3(2):166–173. doi: 10.3945/an.111.001628.
    1. Kaesler N, Magdeleyns E, Herfs M, et al. Impaired vitamin K recycling in uremia is rescued by vitamin K supplementation. Kidney Int. 2014;86(2):286–293. doi: 10.1038/ki.2013.530.
    1. Caluwé R, Pyfferoen L, De Boeck K, De Vriese AS. The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials. Clin Kidney J. 2016;9(2):273–279. doi: 10.1093/ckj/sfv146.
    1. Caluwé R, van Vlem B, Vermeer C, et al. Vitamin K2 supplementation in hemodialysis patients: a randomized dose-finding study. Nephrol Dial Transplant. 2014;29:1385–1390. doi: 10.1093/ndt/gft464.
    1. Westenfeld R, Krueger T, Schlieper G, et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis. 2012;59:186–195. doi: 10.1053/j.ajkd.2011.10.041.
    1. Knapen MH, Braam LA, Drummen NE, Bekers O, Hoeks AP, Vermeer C. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double blind randomized clinical trial. Thromb Haemost. 2015;113(5):1135–1144. doi: 10.1160/TH14-08-0675.
    1. Raggi P, Bellasi A. Clinical assessment of vascular calcification. Adv Chronic Kidney Dis. 2007;14:37–43. doi: 10.1053/j.ackd.2006.10.006.
    1. Cranenburg EC, Schurgers LJ, Uiterwijk HH, et al. Vitamin K intake and status are low in hemodialysis patients. Kidney Int. 2012;82(5):605–610. doi: 10.1038/ki.2012.191.
    1. Theuwissen E, Magdeleyns EJ, Braam LA, et al. Vitamin K status in healthy volunteers. Food Funct. 2014;5(2):229–234. doi: 10.1039/C3FO60464K.
    1. Liabeuf S, Bourron O, Vemeer C, et al. Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein. Cardiovasc Diabetol. 2014;13:85. doi: 10.1186/1475-2840-13-85.
    1. Schlieper G, Westenfeld R, Krüger T, et al. Circulating Nonphosphorylated Carboxylated matrix Gla protein predicts survival in ESRD. J Am Soc Nephrol. 2011;22(2):387–395. doi: 10.1681/ASN.2010040339.
    1. Kurnatowska I, Grzelak P, Masajtis-Zagajewska A, et al. Plasma Dephospho-Uncarboxylated matrix Gla protein as a marker of kidney damage and cardiovascular risk in advanced stage of chronic kidney disease. Kidney Blood Press Res. 2016;41:231–239. doi: 10.1159/000443426.
    1. Hayashi M, Takamatsu I, Kanno Y, et al. Japanese Calciphylaxis study group. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant. 2012;27:1580–1584. doi: 10.1093/ndt/gfr658.
    1. Krüger T, Floege J. Vitamin K antagonists: beyond bleeding. Semin Dial. 2014;27:37–41. doi: 10.1111/sdi.12175.
    1. Brandenburg V, Evenepoel P, Floege J, et al. Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis? Nephrol Dial Transplant. 2016;31(8):1211–1219. doi: 10.1093/ndt/gfw025.
    1. Vissers LE, Dalmeijer GW, Boer JM, et al. Intake of dietary phylloquinone and menaquinones and risk of stroke. J Am Heart Assoc. 2013;2:6. doi: 10.1161/JAHA.113.000455.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다